Insights
Category: NewCo
-
Why the next wave of pharma value will be sourced, not invented in-house
Why leading biotechs are shifting from internal R&D to sourced innovation across borders.
-
Reading a data package the way a strategic buyer will
How to structure and present a data room so strategic acquirers move faster.
-
Structuring milestones that hold up after the deal closes
Designing earn-outs and milestones that survive integration and shifting priorities.
-
The Gulf as capital partner, not just a market
Why Gulf sovereign and family capital is becoming a strategic partner in life-science deals.
-
NewCo or sell-down: choosing the right path for a carve-out
A framework for deciding between spinning out a NewCo and selling down an asset.
-
What changed in cross-border China biotech partnering this year
The shifts in regulation and deal structure reshaping China biotech partnerships.